Zhitong Financial APP News, Enwei Medicine (301331Acernitro5unboxing.SZ) issued the 2023 annual performance report, during the reporting period, the company realized operating income of 785 million yuan, an increase of 13.54% over the same period last year; it belongs to shareholders of listed companies.Acernitro5unboxingThe net profit was 86.3123 million yuan, an increase of 27.3% over the same period last year; the net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 73.585 million yuan, an increase of 28.62% over the same period last year; and basic earnings per share was 1.2317 yuan. The company intends to distribute cash dividends of 8 yuan (including tax) to all shareholders and 0 shares (including tax) to all shareholders.

The company is mainly engaged in the research and development, production and sales of proprietary Chinese medicine and chemical drugs, focusing on gynecological products, pediatric drugs, respiratory system drugs and other fields. According to the Industry Classification guidelines of China Securities Regulatory Commission (revised in 2012), the company belongs to the pharmaceutical manufacturing industry in the manufacturing industry (industry code "C27").

Jieeryin lotion for external gynecology is the core product of the company. in addition, the company also develops disinfection products such as ointment, suppositories, capsules, effervescent tablets and bacteriostatic lotion, and develops a series of gynecological medicine products by means of independent research and development, joint research and development, and purchasing varieties, so as to continuously maintain and further enhance the company's leading position in the field of domestic gynecological products. While taking gynecological products as the core, the company continues to expand the product extension by giving full play to the advantages of brand and sales channels, and actively develops pediatric and respiratory drugs. form a diversified product group covering the reproductive system, digestive system, respiratory system and other areas. At present, the company has 21 exclusive varieties, including Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Jianer pills, Shanmai Jianpi oral liquid, Huayu Shujing capsule, Yifei Jianpi granule, Ganmaoshu granule, and so on. And the sales revenue of the exclusive varieties during the reporting period accounted for more than 50% of the main business income.